The Top and Bottom Contributors to S&P 500's Q4 EPS Growth

Seeking Alpha12minutes ago

Express News | Eli Lilly and Co expects that its experimental weight-loss drug will be approved as early as early 2026.

BreakingsJan 13 23:42

Express News | Eli Lilly Is Projecting Approval of Its Experimental Weight-Loss Pill as Soon as Early 2026 - Bloomberg News

BreakingsJan 13 23:41

Eli Lilly and Co (LLY.US) has spent 2.5 billion dollars to acquire cancer drug developer Scorpion Therapeutics.

Eli Lilly and Co (LLY.US) announced on Monday plans to acquire Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash, in order to expand its cancer treatment portfolio. The company will acquire Scorpion's experimental oral therapy STX-478, which is currently undergoing early trials for breast cancer and other advanced solid tumors.

AASTOCKSJan 13 23:19

Express News | Eli Lilly and Co will acquire Scorpion's cancer drugs for up to $2.5 billion.

BreakingsJan 13 22:44

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5B Deal

WSJJan 13 22:19